Kyowa Kirin Announces Agreement with U.S. Administration to Reduce Treatment Costs for AmericansTOKYO and PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced a voluntary agreement with the U.S. government to improve access and lower the cost of medicines for American patients.
Kyowa Kirin Introduces Family Outreach Initiative to Support Families Living with XLHNew resources and events help guide meaningful conversations about the hereditary nature of XLH
FDA Selects Kyowa Kirin for PreCheck Pilot Program to Accelerate Manufacturing Timelines and Enhance Supply Chain ResilienceStrategic collaboration at Sanford, North Carolina facility, currently under construction, to optimize cGMP validation, accelerate time-to-market for complex biologics, and shore up U.S. medicine supply
